Mitapivat
Brand names: Aqvesme · Active ingredient: Mitapivat
In short: AQVESME is indicated for the treatment of anemia in adults with alpha- or beta-thalassemia.
What is Mitapivat used for?
AQVESME is indicated for the treatment of anemia in adults with alpha- or beta-thalassemia.
âš Boxed warning (FDA's strongest warning)
AQVESME can cause serious hepatocellular injury. Measure liver laboratory tests (ALT, AST, alkaline phosphatase, and total bilirubin with fractionation) at baseline and every 4 weeks for 24 weeks and then as clinically indicated. Avoid use of AQVESME in patients with cirrhosis. Discontinue AQVESME if hepatic injury is suspected
.
Because of the risk of hepatocellular injury, AQVESME is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the AQVESME REMS
.
Mitapivat dosage
AQVESME is taken with or without food.
Swallow tablets whole. Do not split, crush, chew, or dissolve the tablets.
If a dose of AQVESME is missed by 4 hours or less, administer the dose as soon as possible. If a dose of AQVESME is missed by more than 4 hours, do not administer a replacement dose, and wait until the next scheduled dose. Subsequently, return to the normal dosing schedule.
Monitor for hepatocellular injury during treatment with AQVESME
.
The recommended dosage for adults with alpha- or beta-thalassemia is AQVESME 100 mg orally twice daily.
Treatment with AQVESME is intended to be long-term. Discontinue AQVESME if no benefit in hemolytic anemia has been observed, based on the totality of laboratory results and clinical status of the patient, unless there is another explanation for response failure (e.g., bleeding, surgery, other concomitant illnesses).
Interruption or Discontinuation
If a patient needs to interrupt or discontinue AQVESME for any reason, a dose taper is not necessary.
Prior to Initiating Treatment with AQVESME
Check liver tests including ALT, AST, alkaline phosphatase, total bilirubin with fractionation, before first AQVESME dose.
During Treatment with AQVESME
After the first dose, check liver tests including ALT, AST, alkaline phosphatase, total bilirubin with fractionation every 4 weeks for 24 weeks and as clinically indicated thereafter.
When Drug-Induced Liver Injury Is Suspected
Interrupt AQVESME and complete a comprehensive evaluation to rule out other causes of liver injury.
If AQVESME-related liver injury caused new or worsening jaundice or ALT ≥10×baseline, do NOT restart AQVESME.
If AQVESME-related liver injury is not ruled out, but peak ALT is <10×baseline without elevation of bilirubin above baseline, and if AQVESME is resumed, reinitiate liver test monitoring every 4 weeks for 24 additional weeks.
If AQVESME-related liver injury is ruled out, AQVESME may be restarted at provider discretion. Resume liver test monitoring schedule that existed prior to stopping AQVESME.
AQVESME
Interruption Due to Non-Liver Causes
If AQVESME was stopped for any reason for ≤8 weeks other than suspected AQVESME-related liver injury, resume the liver test monitoring schedule that existed prior to stopping AQVESME.
If AQVESME was stopped for more than 8 weeks, restart liver test monitoring every 4 weeks for 24 additional weeks upon resumption of treatment with AQVESME.
If treatment is stopped for any duration after 24 weeks of monitoring and treatment, resume monitoring as clinically indicated.
Moderate CYP3A Inducers
Consider alternative therapies that are not moderate CYP3A inducers during treatment with AQVESME. …
How to take Mitapivat — instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (Medication Guide).
Hepatocellular Injury
Inform patients of the risk of hepatocellular injury with AQVESME. In patients with thalassemia treated with AQVESME, liver injury has been observed within the first 6 months of treatment. Tell patients to immediately report any new or worsening symptoms suggestive of liver injury including loss of appetite, nausea, right upper quadrant abdominal pain, vomiting, scleral icterus, jaundice, or dark urine on AQVESME treatment to their healthcare provider for further evaluation
.
AQVESME REMS
AQVESME is only available through a restricted program called the AQVESME REMS
.
Inform the patient of the following notable requirements:
Patients must enroll in the REMS and comply with the REMS requirements.
AQVESME is available only from certified pharmacies participating in the REMS. Therefore, provide patients with the telephone number and website for information on how to obtain AQVESME.
Drug Interactions
Advise patients to inform their healthcare providers of all concomitant medications, including over-the-counter medications, vitamins, and herbal products
. …
Warnings & precautions
Do not take this medicine if: None.
AQVESME can cause hepatocellular injury. Avoid use of AQVESME in patients with cirrhosis. In patients with thalassemia treated with AQVESME, liver injury with and without jaundice has been observed within the first 6 months of exposure. Obtain liver tests (including ALT, AST, alkaline phosphatase, total bilirubin with fractionation) prior to the initiation of AQVESME, then every 4 weeks for the first 24 weeks, and as clinically indicated thereafter. Interrupt AQVESME if clinically significant increases in liver tests are observed or alanine aminotransferase is >5 times the upper limit of normal (ULN). Complete a comprehensive evaluation to rule out other causes of liver injury when drug-induced liver injury (DILI) is suspected. Discontinue AQVESME if hepatocellular injury due to AQVESME is suspected
.
Symptoms and signs of early liver injury may mimic those of thalassemia. Advise patients to report new or worsening symptoms of loss of appetite, nausea, right upper quadrant abdominal pain, vomiting, scleral icterus, jaundice, or dark urine while on AQVESME treatment.
During the double-blind period, 2 of 301 patients (0.66%) with thalassemia treated with AQVESME experienced adverse reactions suggestive of hepatocellular injury. Three additional patients experienced adverse reactions suggestive of hepatocellular injury during the open-label extension periods after switching from placebo to AQVESME. Of these 5 patients, two had serious liver injury and were hospitalized including 1 patient who developed jaundice (peak bilirubin 32 mg/dL). Another patient developed jaundice (peak bilirubin 4 mg/dL) without being hospitalized. These reactions were characterized by a time to onset within the first 6 months of treatment with peak elevations of alanine aminotransferase of >5×ULN with or without jaundice. …
Mitapivat side effects
The following clinically significant adverse reaction is described elsewhere in labeling:
Hepatocellular Injury
.
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Alpha- and Beta-Thalassemia
A total of 301 patients with thalassemia received AQVESME, administered at 100 mg orally twice daily, for up to 59.9 weeks in the ENERGIZE trial (N=129) and the ENERGIZE-T trial (N=172)
.
ENERGIZE Trial
Patients with non-transfusion-dependent thalassemia received AQVESME (N=129) or placebo (N=63).
The most common adverse reactions (≥5% and at least 5% higher in the AQVESME arm) in patients with non-transfusion-dependent thalassemia were headache and insomnia.
ENERGIZE-T Trial
Patients with transfusion-dependent thalassemia received AQVESME (N=172) or placebo (N=85).
The most common adverse reactions (≥5% and at least 5% higher in the AQVESME arm) in patients with transfusion-dependent thalassemia were headache and insomnia.
Serious adverse reactions occurred in 1.3% of patients with thalassemia treated with AQVESME, including supraventricular arrhythmia and supraventricular tachycardia. Permanent discontinuations of AQVESME due to an adverse reaction occurred in 1.3% of patients and included elevated hepatic transaminases and insomnia. …
Drug interactions
Strong CYP3A Inhibitors
Clinical Impact | Co-administration of AQVESME with strong CYP3A inhibitors increased mitapivat plasma concentrations
.
Increased mitapivat plasma concentrations may increase the risks of adverse reactions of AQVESME.
Prevention or Management | Avoid co-administration of strong CYP3A inhibitors with AQVESME
.
Moderate CYP3A Inhibitors
Clinical Impact | Co-administration of AQVESME with moderate CYP3A inhibitors will increase mitapivat plasma concentrations
.
Prevention or Management | Avoid co-administration of moderate CYP3A inhibitors with AQVESME
.
Strong CYP3A Inducers
Clinical Impact | Co-administration of AQVESME with strong CYP3A inducers decreased mitapivat plasma concentrations
.
Decreased mitapivat plasma concentrations will reduce the efficacy of AQVESME.
Prevention or Management | Avoid co-administration of strong CYP3A inducers with AQVESME
.
Moderate CYP3A Inducers
Clinical Impact | Co-administration of AQVESME with moderate CYP3A inducers will decrease mitapivat plasma concentrations
.
Prevention or Management | Consider alternative therapies that are not moderate CYP3A inducers during treatment with AQVESME. If there are no alternative therapies, monitor Hb and do not exceed the maximum recommended dose of 100 mg twice daily
. …
About this medicine
The active ingredient of AQVESME is mitapivat, a pyruvate kinase activator, present as mitapivat sulfate. The chemical name of mitapivat sulfate is 8-quinolinesulfonamide, N-[4-[[4- (cyclopropylmethyl)-1-piperazinyl]carbonyl]phenyl]-, sulfate, hydrate (2:1:3). The chemical structure of mitapivat sulfate is:
The molecular formula is (C24H26N4SO3)2 • H2SO4 • 3H2O, and the molecular weight is 1053.23 for mitapivat sulfate. Mitapivat sulfate is a white to off-white solid and is slightly soluble in water.
AQVESME is available as 100 mg tablets for oral administration. Each tablet contains 100 mg mitapivat free base, provided as 117.0 mg of the sulfate hydrate salt, and the following inactive ingredients: croscarmellose sodium, mannitol, microcrystalline cellulose, and sodium stearyl fumarate.
The 100 mg tablet film coating contains the inactive ingredients FD&C Blue No. 2, hypromellose, lactose monohydrate, titanium dioxide, triacetin, and macrogol/PEG. The tablets are imprinted with blue ink containing the inactive ingredients ammonium hydroxide, FD&C Blue No. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 1d4e2654-1636-0d01-e063-6394a90af303. Read the full official label on DailyMed.